Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ: BBIO )

35.49 +0.59 (+1.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
LianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial
Via Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX... 
Via Benzinga
BridgeBio Starts Dosing In Early-Stage Genetic Metabolism Disorder Trial
Via Benzinga
BridgeBio Pharma Touts Encouraging Data From Dwarfism Candidate
Via Benzinga
BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease
Via Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis. 
Via Benzinga
BridgeBio Pharma Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q2, BridgeBio Pharma (NASDAQ:BBIO) posted sales of $73.75 million. Earnings were up 98.73%, but BridgeBio Pharma still reported an overall loss of $2.56 million. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate
Via Benzinga
Where BridgeBio Pharma Stands With Analysts
BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative'
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
BridgeBio Shares Fall As Initial-Stage Rare Metabolic Disorder Study Kicks-off
BridgeBio Pharma (NASDAQ: BBIO) has dosed first patient in its Phase 1 clinical trial of BBP-671, an investigational oral therapy being developed for the potential treatment of conditions caused by... 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial
BridgeBio Pharma Inc (NASDAQ: BBIO)  
Via Benzinga
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1. 
Via Benzinga
BridgeBio Pharma Reveals Early Positive Data For Canavan Disease
BridgeBio Pharma (NASDAQ: BBIO) announced early positive data from the the first two participants dosed in CANaspire clinical study for the treatment of Canavan disease. 
Via Benzinga
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
BridgeBio Pharma's Return On Capital Employed Insights
Benzinga Pro data, BridgeBio Pharma (NASDAQ:BBIO) reported Q1 sales of $1.69 million. Earnings fell to a loss of $201.33 million, resulting in a 32.21% decrease from last quarter. 
Via Benzinga
6 Analysts Have This to Say About BridgeBio Pharma
Over the past 3 months, 6 analysts have published their opinion on BridgeBio Pharma (NASDAQ:BBIO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder
Via Benzinga
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
What 6 Analyst Ratings Have To Say About BridgeBio Pharma
BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
Where BridgeBio Pharma Stands With Analysts
Analysts have provided the following ratings for BridgeBio Pharma (NASDAQ:BBIO) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market
BridgeBio Pharma Inc (NASDAQ: BBIO) has announced data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), a group... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.